Our data elucidates a function of PRKAR2A deficiency in ameliorating DSS-induced colitis, which was earlier unidentified, thus suggesting that PRKAR2A might contribute to the unsatisfactory results of PDE4 inhibitor in the IBD clinical trial. The gene discussed is PRKAR2A; the disease is inflammatory bowel disease.